PRM150 Methods And Context For The Production Of Rapid Reviews  by Kato, E.U.
A36  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  
decrease in medical errors; positive ROI and meeting government expectations for 
healthcare reform (including ACO, PCMH, PQRS, MU). ePRO benefits include: over-
coming paper limitations (illegible patient entries, large amounts of missing data, 
easily destroyed, no time/date stamps); more easily integrated; readiness to analyze; 
higher quality data; easier for sites/sponsors to obtain information; increased effi-
ciency; increased compliance; easier to monitor patient safety; decrease in errone-
ous data; reduction in patient/site burden. Most reasons for increased EMR adoption 
in clinical practice are similar to ePRO benefits for clinical research. Major reasons 
for EMR adoption are positive ROI associated with higher quality data and meet-
ing government expectations. Clinical research still needs to recognize the overall 
positive ROI, since start-up costs are higher with ePRO. ePRO can pose an overall 
positive ROI when looking at the costs savings associated with higher quality data. 
While regulatory authorities recognize ePRO benefits, additional regulatory support 
would also render higher ePRO adoption rate.
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BAckground: Systematic reviews (SRs) are critically important to support deci-
sion making in health care. Interest in reliable and quick evidence synthesis has 
sparked development of “rapid reviews” yet no clear consensus exists on what 
these are or what processes they use. The goal of this project was to understand 
and describe practices of conducting rapid reviews. Methods: We searched the 
literature to identify rapid review methods, guidance, and empiric evidence, and 
conducted interviews with organizations that produce rapid reviews to identify 
current practices, and understand the evolution of their programs and products. We 
analyzed the data qualitatively, integrating information gathered from the literature 
and interviews. results: We identified 36 rapid products from 20 organizations 
(production time, 5 minutes to 8 months). Almost all products used four approaches 
to save time (restricted database searching, inclusion criteria, data abstraction, and 
dual review); with faster products tending to employ more of these approaches. 
Methods also varied by synthesis type, with some products (Inventories) avoiding 
synthesis completely, while others (Rapid reviews) performed syntheses similar to 
full reviews but with limited scope and review to achieve deadlines. Interviews with 
producers provided insight into these variations. Most rapid products are produced 
to support specific decisions in an identified timeframe within the context of a 
close relationship between researcher and end-user. This allows selection of meth-
ods that best fit the decision and timeframe, and helps the end-user understand 
resulting limitations. Almost no empiric evidence exist comparing rapid reviews 
and SRs. conclusions: Rapid products have tremendous methodological varia-
tion, but categorization based on timeframe or type of synthesis reveals some pat-
terns. This variation in methods results in part from the close relationship between 
reviewer and end-user. Organizations considering production or consumption of 
rapid review products need to consider this context and other factors.
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resource Modelling: the Missing Piece oF the htA JigsAW?: Within health 
technology assessment (HTA), cost-effectiveness analysis and budget impact analyses 
have been broadly accepted as important components of decision making. However, 
whilst they address efficiency and affordability, the issue of implementation and 
feasibility has been largely ignored. HTA commonly takes place within a deliberative 
framework that captures issues of implementation and feasibility in a qualitative 
manner. Economic analyses typically ignore the short-term constraints (e.g. beds, 
availability of computed tomography scanners, nurses) that might lead to low levels 
of uptake. We argue that only through a formal quantitative assessment of resource 
constraints can these issues be fully addressed. Analyses that do not consider these 
issues run the risk of recommending technologies that cannot be delivered within 
the expected time frame, or which require higher than expected costs to ensure 
delivery thereby reducing the cost effectiveness of the recommendation. We argue 
that resource modelling is required for uptake to be formally considered by decision 
makers. We define resource modelling as a quantitative assessment of technology 
diffusion, its related resource requirements and capacity constraints. Resource mod-
elling is especially useful if there are significant changes in the amount or type of 
resources needed within the pathway by implementing the new technology. We will 
describe the usefulness of resource modelling along with examples from the litera-
ture. We describe the modelling techniques (discrete event simulation and system 
dynamics) which can capture these resource implications and highlight that these 
analyses can be performed at a national or organisational level. Finally, important 
issues that need to be considered when undertaking resource modelling are described 
before setting out recommendations for the use of resource modelling in HTA. Further 
research should examine the potential use of operational research techniques in the 
assessments of cost effectiveness and feasibility.
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This conceptual paper will illustrate the impacts of low quality data, describe the 
requirements of the data cleaning process, compare the data cleaning process for 
paper versus ePRO, and provide recommendations of how ePRO can be implemented 
to decrease the level of effort of data cleaning. Before data can be analyzed, data 
cleaning must occur to ensure high data quality. Low quality data can have major 
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MaRS EXCITE is an innovation in health technology assessment (HTA) where 
industry, academia, and the health system collaborate to design and execute a 
robust evaluation program for innovative medical technologies with high disruptive 
potential that proactively satisfies regulatory and reimbursement decision-mak-
ers requirements. EXCITE compromises five Methodological Centres (MCs) across 
Ontario, Canada with demonstrated excellence in methodologies for designing and 
conducting complex, multi-centre trials and HTAs. The MCs develop the protocol 
collaboratively with industry and experts, and oversee the clinical trials, involv-
ing multiple participating sites. In an attempt to promote consistency in Quality 
Assurance (QA) amongst MCs and participating sites for EXCITE studies, EXCITE 
has developed SOPs, through the Clinical Trials Methodology Committee, that relate 
exclusively to the unique collaboration with the MCs. These were developed through 
an analysis of host institution SOPs and developing overarching SOPs that were 
either unique to the EXCITE QA program, or where deemed appropriate though 
lacking from some host institutions. This harmonization of SOPs across the five 
current EXCITE MCs has allowed EXCITE to address one of the main goals of clinical 
trial QA that is integrity of data. The second goal of clinical trial QA, patient safety, 
is achieved through the Safety Advisory committee, which sets safety standards 
that must be adhered to by the MCs evaluating the technologies. The committee 
reviews all protocols to ensure that patient safety issues are addressed,makes rec-
ommendations for protocol changes as necessary and may also mandate training 
requirements to ensure competency in utilization of any medical technology under-
going testing in the EXCITE program. Therefore, MaRS EXCITE was able to deploy 
a collaborative platform to harmonize the QA processes across five independent 
academic methodological centres in order to conduct efficient and effective clini-
cal trials that are used in evaluating disruptive medical technologies in an effort to 
optimize patient outcomes.
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There is increasing interest in innovation in the development and validation of 
clinical outcome assessments (COAs), fuelled by the need to demonstrate robust 
evidence of content validity for regulatory approval with ever increasing budget 
and time constraints. Traditionally, qualitative research methods have relied upon 
standard one-one interview and focus groups techniques; however these may not 
always be appropriate, particularly for patients with communication difficulties 
or in pediatric populations or for sensitive research areas. Creative methodolo-
gies can be a pragmatic way to elicit patient-driven insights and identify appropri-
ate outcomes in special populations. There is a well-established literature base 
exploring the use of creative methodologies in social research and many of these 
approaches can be readily applied to outcomes research. We have reviewed a vari-
ety of creative methods and purposively selected the most valuable approaches to 
create a toolkit of methods to advance the development of patient-centred COAs. 
The toolkit of creative methods is discussed in context of: 1) disease and clinical 
characteristics, 2) patient demographics and 3) research objectives. Integration of 
creative methodologies throughout the COA development process serves to develop 
patient-driven insights for concept elicitation and item generation. By advancing 
elicitation techniques (e.g. visual elicitation), and ecological evidence generation 
(e.g. video diaries) participants’ have the power and freedom to show how they per-
ceive and experience their condition, rather than reliance on verbal report. Creative 
methodologies can be used to demonstrate reliable, valid and content rich data 
for a variety of populations and contexts of use. There are exciting opportunities 
to build upon existing practice and advance creative research approaches in this 
field. Integrating such methodologies generates patient insight to underpin content 
development for COAs ensuring they are developed with an evolving fit for pur-
pose approach. The application of such methods for regulatory COA development 
requires further exploration.
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In clinical practice, Electronic Medical Record (EMR) adoption has rapidly increased 
over recent years. In 2013, it was estimated that 78.4% of physician-based practices 
use some type of EMR system (as reported by National Center for Health Statistics). 
In clinical research, electronic Patient Reported Outcomes (ePRO) adoption is mov-
ing slower–where it is estimated that less than half of PRO studies use ePRO. This 
conceptual paper compares EMR benefits of clinical practice with ePRO benefits of 
clinical research and provides recommendations of how clinical research can follow 
clinical practice in benefiting from technology. EMR benefits include: overcoming 
paper limitations (illegible clinician notes, large amounts of missing information, 
easily destroyed, no time/date traceability and whose viewed/accessed); improved 
integrations with other practices/facilities; readiness to analyze; higher quality data; 
easier to obtain payment; easier to provide information to insurance providers; 
increased efficiency; increased compliance; increased quality of care/patient safety; 
